Affordable Access

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.

Authors
  • Neben, K
  • Moehler, T
  • Kraemer, A
  • Benner, A
  • Egerer, G
  • Ho, A D
  • Goldschmidt, H
Type
Published Article
Journal
British journal of haematology
Publication Date
Dec 01, 2001
Volume
115
Issue
3
Pages
605–608
Identifiers
PMID: 11736942
Source
Medline
License
Unknown

Abstract

Thalidomide (Thal) is a drug with anti-angiogenic properties. To explore whether the effect of Thal on angiogenesis is associated with a reduction of angiogenic cytokine levels in progressive multiple myeloma (MM), plasma levels of basic fibroblast growth factor, vascular endothelial growth factor, interleukin 6, tumour necrosis factor-alpha and hepatocyte growth factor (HGF) were measured in 51 patients at 0, 3 and 6 months of Thal therapy. After 6 months of treatment, 26 patients were considered to be responsive to Thal therapy, including 17 minimal responses, eight partial responses and one complete response. Only HGF (decreasing, P = 0.02) in the group of responsive patients showed a statistically significant change over a period of 6 months. Because HGF levels are known to correlate to MM tumour burden, we conclude that the mechanism of action of Thal in MM is not caused by a specific inhibition of angiogenic cytokine secretion.

Report this publication

Statistics

Seen <100 times